Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qingshu-Yiqi-Tang in Advanced Non-Small Cell Lung Cancer
NCT01802021Phase 3Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- May 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Qingshu-Yiqi-Tang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
Qingshu-Yiqi-Tang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01802021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802021.